Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit	Total Vaccinex,Inc. Stockholders' Deficit	Noncontrolling Interests
Balance at Dec. 31, 2018	$ 15,342,000	$ 1,000	$ 208,156,000	$ (11,000)	$ (216,767,000)	$ (8,621,000)	$ 23,963,000
Balance, Shares at Dec. 31, 2018		11,476,601		852
Stock-based compensation	60,000		60,000			60,000
Net loss	(9,067,000)				(9,067,000)	(9,067,000)
Balance at Mar. 31, 2019	6,335,000	$ 1,000	208,216,000	$ (11,000)	(225,834,000)	(17,628,000)	23,963,000
Balance, Shares at Mar. 31, 2019		11,476,601		852
Balance at Dec. 31, 2018	15,342,000	$ 1,000	208,156,000	$ (11,000)	(216,767,000)	(8,621,000)	23,963,000
Balance, Shares at Dec. 31, 2018		11,476,601		852
Net loss	(17,895,000)
Balance at Jun. 30, 2019	(2,380,000)	$ 1,000	208,329,000	$ (11,000)	(234,662,000)	(26,343,000)	23,963,000
Balance, Shares at Jun. 30, 2019		11,481,056		852
Balance at Mar. 31, 2019	6,335,000	$ 1,000	208,216,000	$ (11,000)	(225,834,000)	(17,628,000)	23,963,000
Balance, Shares at Mar. 31, 2019		11,476,601		852
Exchange of Vaccinex Products LP Units for common shares, Shares		4,455
Stock-based compensation	113,000		113,000			113,000
Net loss	(8,828,000)				(8,828,000)	(8,828,000)
Balance at Jun. 30, 2019	(2,380,000)	$ 1,000	208,329,000	$ (11,000)	(234,662,000)	(26,343,000)	23,963,000
Balance, Shares at Jun. 30, 2019		11,481,056		852
Balance at Dec. 31, 2019	(2,274,000)	$ 1,000	222,403,000	$ (11,000)	(248,630,000)	(26,237,000)	23,963,000
Balance, Shares at Dec. 31, 2019		14,887,999		852
Issuance of common shares	7,476,000	$ 1,000	7,475,000			7,476,000
Issuance of common shares, Shares		1,468,563
Stock-based compensation	204,000		204,000			204,000
Stock-based compensation, Shares		20,000
Exercise of stock options	4,000		4,000			4,000
Exercise of stock options, Shares		1,025
Net loss	(7,149,000)				(7,149,000)	(7,149,000)
Balance at Mar. 31, 2020	(1,739,000)	$ 2,000	230,086,000	$ (11,000)	(255,779,000)	(25,702,000)	23,963,000
Balance, Shares at Mar. 31, 2020		16,377,587		852
Balance at Dec. 31, 2019	$ (2,274,000)	$ 1,000	222,403,000	$ (11,000)	(248,630,000)	(26,237,000)	23,963,000
Balance, Shares at Dec. 31, 2019		14,887,999		852
Exercise of stock options, Shares	1,025
Net loss	$ (13,650,000)
Balance at Jun. 30, 2020	(5,578,000)	$ 2,000	232,748,000	$ (11,000)	(262,280,000)	(29,541,000)	23,963,000
Balance, Shares at Jun. 30, 2020		17,023,824		852
Balance at Mar. 31, 2020	(1,739,000)	$ 2,000	230,086,000	$ (11,000)	(255,779,000)	(25,702,000)	23,963,000
Balance, Shares at Mar. 31, 2020		16,377,587		852
Issuance of common shares	2,296,000	$ 642,112,000	2,296,000			2,296,000
Exchange of Vaccinex Products LP Units for common shares, Shares		4,125
Stock-based compensation	366,000		366,000			366,000
Net loss	(6,501,000)				(6,501,000)	(6,501,000)
Balance at Jun. 30, 2020	$ (5,578,000)	$ 2,000	$ 232,748,000	$ (11,000)	$ (262,280,000)	$ (29,541,000)	$ 23,963,000
Balance, Shares at Jun. 30, 2020		17,023,824		852